WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea.

Author: Doosoo JEON ¹
Author Information

1. Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea. sooli10@hanmail.net
Publication Type:Review
Keywords: Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization; Guideline
MeSH: Classification; Humans; Korea*; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant*; World Health Organization
From:Tuberculosis and Respiratory Diseases 2017;80(4):336-343
CountryRepublic of Korea
Language:English
Abstract: Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea.